$OCGN

Ocugen, Inc. (OCGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622368d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Ocugen Provides Business Update with Second Quarter 2026 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET · Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial fo

Ocugen (NASDAQ: OCGN) said it signed a binding term sheet to negotiate an exclusive license for its OCU400 modifier gene therapy for retinitis pigmentosa in the Middle East and North Africa with Roots Pharmaceutical and Al-Dhow International Holding. Ocugen expects up to $4 million in upfront and near-term milestones, up to $255 million in sales milestones, and 22% royalties on net sales. Ocugen will manufacture OCU400, with a definitive deal expected within 90 days.

Johnson-Greene Treerita Essalima (Chief Financial Officer) purchased 21,000 shares of Ocugen, Inc. (OCGN) at $1.23 on 2026-06-15.

Ocugen, Inc. (OCGN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001372299 0001372299 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report

Ocugen, Inc. reported Q1 EPS of (6c) against a consensus of (5c) and revenue of $1.53M, significantly exceeding expectations. The company announced progress in its late-stage clinical programs, including completed enrollment for two trials and plans for BLA submissions for retinitis pigmentosa and OCU410ST, as well as a registration trial for dry AMD. Ocugen also revealed a proposed private offering of $115M in convertible senior notes.

This article provides financial information for Ocugen Inc (A2PSZH) on the Lang & Schwarz Exchange, specifically focusing on the number of shareholders. It appears to be a stub or data reference page from TradingView, offering an overview of the company's financials without detailed analytical content in the provided text. The page highlights market data and general company information, indicating a closed market status.

Ocugen has announced an amended preliminary proxy statement for its Annual Meeting on June 11, 2026, including a proposal for a reverse stock split ranging from 1:2 to 1:8. The company also provided updates on its clinical programs, with OCU400 Phase 3 topline data expected in Q1 2027 and positive Phase 2 results for OCU410. Recent financing activities, totaling $37.5 million, are projected to extend the cash runway into Q1 2027.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed a Schedule 13G disclosing their shared beneficial ownership of 17,074,584 shares of Ocugen, Inc. common stock, representing 5.2% of the class. The filing indicates shared voting and dispositive power over these shares. The Schedule 13G was signed on April 13, 2026, and lists the CUSIP number as 67577C105.

Ocugen, Inc. has commended retinal specialists for their crucial role in advancing modifier gene therapy through clinical trials and advisory input. These experts are instrumental in developing new treatment options for severe blindness conditions that currently have limited therapies. Ocugen continues to push gene therapy innovations in collaboration with leading medical professionals, having recently accelerated efforts in modifier gene therapies and celebrated women leaders in the field.

Ocugen's Q4 earnings call highlighted significant progress in its gene therapy pipeline, particularly OCU400, OCU410, and OCU410ST, with several programs advancing towards Phase 3 trials and potential commercialization. Despite a constrained balance sheet and increased R&D spending leading to wider losses, the company is preparing for commercial scale-up through strategic hires and regional licensing deals. However, liquidity risk remains a concern due to reliance on future funding and the long timelines for revenue generation.